Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Panobinostat in Relapsed and Relapsed/Refractory Myeloma

Studied in combination with bortezomib and dexamethasone

Publish date:: December 9, 2015

Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) demonstrated a clear progression-free survival (PFS) benefit of 7.8 months among patients who received ≥ 2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis. This according to a study of 485 patients with myeloma previously treated with an IMiD, 193 treated with bortezomib plus an IMiD, and 147 with ≥ 2 prior regimens including bortezomib and an IMiD. Researchers’ findings included that median PFS for PAN-BTZ-Dex vs Placebo-BTZ-Dex across subgroups were:

• Prior IMiD (12.3 vs 7.4 months)

• Prior bortezomib plus IMiD (10.6 vs 5.8 months)

• ≥ 2 prior regimens including bortezomib and an IMiD (12.5 vs 4.7 months)

Citation: Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. [Published online ahead of print December 2, 2015]. Blood. doi: 10.1182/blood-2015-09-665018.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,